Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05932836 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 6 more changesShow less
    • Final enrollment: 226 participants (planned 165)
    • Primary completion moved earlier from Dec 31, 2024 to Aug 28, 2024
    • Study completion date changed from estimate of Sep 30, 2025 to May 28, 2025
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description revised
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 31, 2025 to Dec 31, 2024
    • Study completion date: Feb 28, 2026 to Sep 30, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is aimed to establish an organoid-on-chips technological system based on biopsy samples and evaluate its efficacy in predicting the response to mFOLFOX6 infusion in patients with hepatocellular carcinoma (HCC).
Trial Details
NCT Number NCT05932836
Lead Sponsor Xiangya Hospital of Central South University
Conditions
(from sponsor)		 Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 226 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov